- Home
- MQ vs PTGX Comparison
MQ vs PTGX Comparison
Compare MQ & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQ
- PTGX
- Stock Information
- Founded
- MQ 2010
- PTGX 2006
- Country
- MQ United States
- PTGX United States
- Employees
- MQ N/A
- PTGX N/A
- Industry
- MQ Computer Software: Prepackaged Software
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- MQ Technology
- PTGX Health Care
- Exchange
- MQ Nasdaq
- PTGX Nasdaq
- Market Cap
- MQ 1.9B
- PTGX 2.3B
- IPO Year
- MQ 2021
- PTGX 2016
- Fundamental
- Price
- MQ $3.69
- PTGX $38.75
- Analyst Decision
- MQ Hold
- PTGX Strong Buy
- Analyst Count
- MQ 15
- PTGX 8
- Target Price
- MQ $5.50
- PTGX $57.13
- AVG Volume (30 Days)
- MQ 4.4M
- PTGX 528.6K
- Earning Date
- MQ 02-26-2025
- PTGX 02-21-2025
- Dividend Yield
- MQ N/A
- PTGX N/A
- EPS Growth
- MQ N/A
- PTGX N/A
- EPS
- MQ 0.03
- PTGX 4.23
- Revenue
- MQ $490,027,000.00
- PTGX $434,433,000.00
- Revenue This Year
- MQ N/A
- PTGX $445.33
- Revenue Next Year
- MQ $15.46
- PTGX N/A
- P/E Ratio
- MQ $137.42
- PTGX $9.16
- Revenue Growth
- MQ N/A
- PTGX 624.05
- 52 Week Low
- MQ $3.37
- PTGX $24.22
- 52 Week High
- MQ $7.36
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- MQ 45.67
- PTGX 52.47
- Support Level
- MQ $3.58
- PTGX $37.50
- Resistance Level
- MQ $3.97
- PTGX $39.37
- Average True Range (ATR)
- MQ 0.13
- PTGX 1.32
- MACD
- MQ 0.00
- PTGX 0.16
- Stochastic Oscillator
- MQ 29.11
- PTGX 67.70
About MQ Marqeta Inc.
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.